Matthew Sender
Director & ADC Project Lead LigaChem Biosciences
Matthew has 13 years of experience in industry across medicinal chemistry, chemical biology, and ADCs. LigaChem Biosciences for the last two years after 11 with GSK. Matthew has a passion for chemistry, biology and medicine are united in the design and development of ADCs.
Seminars
Tuesday 9th March 2027
Advancing In Vitro Model Selection for Bone Marrow, Liver & Lung to Test Pre Clinical Activity & Toxicity
- LCB43: A next-generation beta glucuronide BCMA ADC for the treatment of multiple myeloma
- Belantamab Mafodotin is a great ADC held back by ocular toxicity
- LigaChem’s ConjuAll platform has clinical evidence of less ocular tox
- LCB43 is a next-generation ADC to address the key limitation of Blenrep
